BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Entecavir (Baraclude) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Entecavir (Baraclude)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05453435-5880@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Entecavir (Baraclude): Phase 2 readout est. (NCT05453435)
DESCRIPTION:Entecavir (Baraclude)\, phase 2\, Chronic Hepatitis B.\nStudy: 
 Entecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cel
 l Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surfac
 e Antigen\, Positive Hepatitis B Core Antibody)\nEstimated primary complet
 ion: December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 ntecavir-baraclude#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05453435
URL:https://assetmemo.bio/drug/entecavir-baraclude#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07816094-5880@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270119
DTEND;VALUE=DATE:20270120
SUMMARY:Entecavir (Baraclude): Phase 4 readout est. (NCT07816094)
DESCRIPTION:Entecavir (Baraclude)\, phase 4\, Chronic Hepatitis B.\nStudy: 
 Comparison of Viral Suppression With 0.5 mg and 1.0 mg Daily Doses of Ente
 cavir in Decompensated HBV Cirrhosis of Liver\nEstimated primary completio
 n: 19 January 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 ntecavir-baraclude#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07816094
URL:https://assetmemo.bio/drug/entecavir-baraclude#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06966232-5880@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270515
DTEND;VALUE=DATE:20270516
SUMMARY:Entecavir (Baraclude): Phase 3 readout est. (NCT06966232)
DESCRIPTION:Entecavir (Baraclude)\, phase 3\, Chronic Hepatitis B.\nStudy: 
 Prophylactic or Preemptive Entecavir in Patients With Gastrointestinal Can
 cer Who Are Inactive Hepatitis B Carriers\nEstimated primary completion: 1
 5 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/entecavir
 -baraclude#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06966232
URL:https://assetmemo.bio/drug/entecavir-baraclude#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07189377-5880@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Entecavir (Baraclude): Phase 4 readout est. (NCT07189377)
DESCRIPTION:Entecavir (Baraclude)\, phase 4\, Chronic Hepatitis B.\nStudy: 
 Combined Light\, ExVivo\, and Antivirals for Recipients of Lungs From HBV 
 Donors\nEstimated primary completion: August 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/entecavir-baraclude#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07189377
URL:https://assetmemo.bio/drug/entecavir-baraclude#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07253220-5880@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Entecavir (Baraclude): Phase na readout est. (NCT07253220)
DESCRIPTION:Entecavir (Baraclude)\, phase na\, Chronic Hepatitis B.\nStudy:
  TAF Monotherapy Versus ETV Combined With TAF on the Efficacy and Prognosi
 s of Immunotherapy for Hepatitis B-Related Hepatocellular Carcinoma\nEstim
 ated primary completion: 30 September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/entecavir-baraclude#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07253220
URL:https://assetmemo.bio/drug/entecavir-baraclude#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07267208-5880@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Entecavir (Baraclude): Phase 2 readout est. (NCT07267208)
DESCRIPTION:Entecavir (Baraclude)\, phase 2\, Chronic Hepatitis B.\nStudy: 
 A Prospective Study to Evaluate the Efficacy and Safety of Entecavir ODT C
 onversion in Stable Liver Transplant Patients\nEstimated primary completio
 n: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 entecavir-baraclude#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07267208
URL:https://assetmemo.bio/drug/entecavir-baraclude#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03933384-5880@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Entecavir (Baraclude): Phase 4 readout est. (NCT03933384)
DESCRIPTION:Entecavir (Baraclude)\, phase 4\, Chronic Hepatitis B.\nStudy: 
 Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepati
 tis B\nEstimated primary completion: 31 December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/entecavir-baraclude#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT03933384
URL:https://assetmemo.bio/drug/entecavir-baraclude#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797231-5880@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Entecavir (Baraclude): Phase 3 readout est. (NCT07797231)
DESCRIPTION:Entecavir (Baraclude)\, phase 3\, Chronic Hepatitis B.\nStudy: 
 Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogu
 es(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepati
 tis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral L
 oad or Poor Response\nEstimated primary completion: September 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/entecavir-baraclude#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07797231
URL:https://assetmemo.bio/drug/entecavir-baraclude#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04942886-5880@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Entecavir (Baraclude): Phase na readout est. (NCT04942886)
DESCRIPTION:Entecavir (Baraclude)\, phase na\, Chronic Hepatitis B.\nStudy:
  Prophylactic Entecavir for HBV Reactivation in Past HBV Infected Patients
  With Hematopoietic Stem Cell Transplantation\nEstimated primary completio
 n: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 entecavir-baraclude#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04942886
URL:https://assetmemo.bio/drug/entecavir-baraclude#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07345624-5880@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Entecavir (Baraclude): Phase 4 readout est. (NCT07345624)
DESCRIPTION:Entecavir (Baraclude)\, phase 4\, Chronic Hepatitis B.\nStudy: 
 Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 
 Years With Immune-Tolerant Chronic Hepatitis B\nEstimated primary completi
 on: 31 December 2030. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /entecavir-baraclude#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07345624
URL:https://assetmemo.bio/drug/entecavir-baraclude#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07345611-5880@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Entecavir (Baraclude): Phase 4 readout est. (NCT07345611)
DESCRIPTION:Entecavir (Baraclude)\, phase 4\, Chronic Hepatitis B.\nStudy: 
 Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 
 Years With Immune-Active Chronic Hepatitis B\nEstimated primary completion
 : 31 December 2030. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 ntecavir-baraclude#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07345611
URL:https://assetmemo.bio/drug/entecavir-baraclude#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
